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Abstract
We report a case of a 22-year-old female patient who was diagnosed with a cribriform-morular variant of papillary thy-
roid carcinoma (CMV-PTC). While at early ages this thyroid cancer variant is highly suggestive for familial adenomatous 
polyposis (FAP), there was no family history of FAP. In the tumor biallelic, inactivating APC variants were identified. The 
patient tested negative for germline variants based on analysis of genomic DNA from peripheral blood leukocytes. Somatic 
mosaicism was excluded by subsequent deep sequencing of leukocyte and normal thyroid DNA using next generation 
sequencing (NGS). This report presents a rare sporadic case of CMV-PTC, and to the best of our knowledge the first featuring 
two somatic APC mutations underlying the disease, with an overview of CMV-PTC cases with detected APC and CTNNB1 
pathogenic variants from the literature.
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Introduction
The cribriform-morular variant of papillary thyroid carci-
noma (CMV-PTC) is a rare subtype of differentiated thyroid 
cancer and generally has a good prognosis [1]. CMV-PTC is 
highly associated with heterozygous germline APC mutations 
leading to familial adenomatous polyposis (FAP) [2, 3]. FAP, 
an autosomal dominant disorder, is characterized by multiple 
adenomatous colorectal polyps, often showing progression 
into adenocarcinoma and predisposition for a large spectrum 
of extracolonic tumors, including thyroid cancer. De novo 
APC mutations are reported in 11–25% of FAP patients [4, 
5]. About 39–53% of reported CMV-PTC cases in literature 
were found to harbor a germline APC variant or were clini-
cally diagnosed with FAP [6, 7]. However, CMV-PTC may 
also occur sporadically in the absence of FAP.
CMV-PTC has a distinctive histologic morphology fea-
turing morules and a cribriform growth pattern, which is 
related to the permanent activation of the Wnt pathway, and 
reflected by nuclear β-catenin staining on immunohisto-
chemistry (IHC) [1, 8]. The latter may result from biallelic 
APC gene inactivation, or from somatic mutations of the 
β-catenin (CTNNB1) [8–12] or AXIN1 gene (or combina-
tions of gene variants), that are functionally similar [1, 13]. 
As the APC gene acts as a negative regulator of the Wnt 
pathway, mutated APC may result in a truncated protein 
lacking the majority of β-catenin binding sites, consequen-
tially being unable to degrade β-catenin along with cyto-
plasmic and nuclear storage, while regulation of the latter is 
critical to the tumor suppressive effect of APC [14].
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Here we present an extremely rare case of a young woman 
with sporadic CMV-PTC, in whom biallelic somatic inacti-
vating APC variants were detected.
Case description
A 22-year-old female with an unremarkable medical history 
and negative family history for thyroid disease, presented 
with a palpable thyroid mass. Ultrasonography revealed a 
solitary thyroid nodule, measuring 1.5 cm by 1.8 cm by 
2.1 cm, located on the right lobe, with an isoechoic and 
hyper-vascular composition. Cytologic findings on fine-nee-
dle aspiration (FNA) of the nodule were suggestive of PTC 
(Bethesda V). Total nucleic acid (undivided DNA and RNA) 
was isolated from FNA material using a fully automated 
extraction procedure [15]. No somatic DNA variants were 
identified upon analysis with a customized NGS AmpliSeq 
Cancer Hotspot Panel which includes well known thyroid 
carcinoma driver genes (e.g. BRAF, NRAS, HRAS, KRAS, 
TP53, PIK3CA and CTNNB1). A total thyroidectomy was 
performed with intraoperative frozen-section biopsy that 
was concordant with FNA findings. Histologically, the 
encapsulated tumor was highly cellular and composed of a 
combination of trabecular, solid, cribriform and follicular 
growth patterns with morules (Online Resource 1). Immu-
nohistochemical (IHC) analysis for β-catenin, performed as 
previously described [16], showed both positively stained 
nuclei and cytoplasm, indicative of activation and charac-
teristic for CMV-PTC [3].
APC was sequenced as previously described [17], on 
tumor DNA extracted from formalin-fixed, paraffin-embed-
ded (FFPE) tissue cores.
Biallelic, class 4 (likely pathogenic) and class 5 (patho-
genic), respectively, somatic inactivating APC variants 
were identified (NM_000038.5): c.3124delA, p. (Ser-
1042Valfs*14) and c.3183_3187delACAAA, p. (Gln1062*) 
(Online Resource 2).
To explore the chances for having FAP based on these 
findings, the patient was referred for genetic counselling. 
There was no family history of any FAP related tumors, in 
particular, no colon cancer or colonic polyposis. Genomic 
DNA was extracted from peripheral blood leukocytes 
according to standard procedures using Sanger sequencing 
and multiplex ligation-probe amplification (MLPA). All 15 
exons of the APC gene tested negative for germline variants. 
Subsequent screening of DNA from leukocytes and normal 
thyroid tissue for the two somatic APC variants was per-
formed using NGS deep sequencing (coverage of the variant 
region minimally 1000 ×). The specific variants were not 
identified in the leukocyte DNA or normal thyroid, exclud-
ing somatic mosaicism. Therefore, referral for endoscopic 
surveillance, as well as genetic counselling of related family 
members was considered unwarranted. As standard of care, 
the patient received complementary ablation therapy with 
radioactive iodine. The patient had a total remission and also 
no recurrence was noted during follow up.
Literature overview
In Table 1 an overview of pathogenic variants in APC or 
CTNNB1 genes detected in 44 cases of CMV-PTC patients 
reported in literature is listed (Table 1). We conducted a 
Pubmed search on English literature using a combination of 
the terms: cribriform-morular, cribriform or morul* com-
bined with thyroid carcinoma. Most of selected papers were 
reported in the reviews by Lam et al. [7] and/or Pradhan 
et al. [6] and additional relevant papers were found through 
cross-referencing. Reported variants in literature linked to 
the Catalogue of Somatic Mutations in Cancer (COSMIC) 
database (https ://cance r.sange r.ac.uk/cosmi c) and NCBI 
ClinVar (https ://www.ncbi.nlm.nih.gov/clinv ar/) or vari-
ants that could be retrieved from Leiden Open-source Vari-
ation Database (LOVD) (http://www.lovd.nl/3.0/home) were 
listed and annotated according to the Human Genome Vari-
ation Society (HGVS) guidelines for nomenclature (http://
www.hgvs.org/conte nt/guide lines ).
Pathogenic APC variants were described in 39 cases. Of 
these, 36 cases had a germline APC variant including one 
whole gene deletion. Six of those cases with a germline APC 
variant were shown to harbor one additional somatic APC 
variant or per tumor nodule a distinct variant or LOH. One 
case with a germline APC variant harbored two concurrent 
somatic CTNNB1 variants at a different tumor site each. 
Three cases were reported with one somatic APC mutation 
solely. APC germline variants were located between codons 
140 and 1309 and APC somatic variants between codons 
308–1556. Only a limited number of cases were analyzed 
for LOH of the APC gene [9, 12, 20–22].
Six cases have been reported with somatic CTNNB1 
mutations, comprising 8 different variants of CTNNB1, all of 
them located on exon 3. Four cases harbored single somatic 
CTNNB1 variants. One case harbored two somatic CTNNB1 
mutations, both in different tumor nodules.
Reported mutations occurring in other than the afore-
mentioned genes in Table 1, include two somatic mutations 
in exon 7 and 1 of AXIN1, that codes for a scaffold pro-
tein in the multimolecular complex that is formed by the 
APC protein with β-catenin and glycogen synthase kinase 
3 β (GSK-3β), in a familial and a sporadic case of CMV-
PTC, respectively [1, 13]. Furthermore, one apparently spo-
radic 45-year-old female patient case with CMV-PTC and 
a somatic TERT promoter mutation (c. 124C>T) showed 
an aggressive disease course, in absence of an APC muta-
tion; CTNNB1 was not evaluated in this case [37]. RET/
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Table 1  Overview of likely pathogenic APC and CTNNB1 gene variants in CMV-PTC patient cases reported in literature
Sex age Germline pathogenic 
APC variant
Exon T Somatic pathogenic APC 
variant
Exon LOH Somatic patho-
genic CTNNB1 
variant
Exon References
F 23 yr – T1 – – c.65T>C, 
p.(Val22Ala)
3 [9]
T2 – – c.166G>A, 
p.(Asp56Asn)
3
F 20 yr – – ND c.110C>T, 
p.(Ser37Phe)
3 [8]
F 34 yr – – – c.85T>C, 
p.(Ser29Pro)
3 [9]
F 22 yr – – – c.160G>A, 
p.(Glu54Lys)
3 [9]
F 23 yr ND ND ND c.115G>A, 
p.(Ala39Thr)
3 [9]
F 30 yr c.1538delT, 
p.(Val513Glufs*10)
11 T1 – – c.145A>G, 
p.(Lys49Glu)
3 [9, 18]
T2 – – c.131C>T, 
p.(Pro44Leu)
3
F 29 yr Whole gene deletion c.1548+1G>A, splice site 
 variantd
e + ND [19]
F 25 yr c.1660C>T 
p.(Arg554*)
13 T1 c.922delC, 
p.(Leu308fs*28)
8 – – [20]
T2 c.2706_2725del20, 
p.(Glu902fs*3)
15 – –
T3 c.1821delT, 
p.(Cys607fs*3)
14 – –
T4 c.1920delG, 
p.(Asn641fs*5)
14 – –
T5 c.2803_2804insA, 
p.(Tyr935fs*1)
15 – –
T6 c.1602delA, 
p.(Lys534fs*15)
12 – –
F 20 yr c.3329C>G, 
p.(Ser1110*)
15 T1 c.3180_3184delAAAAC, 
p.(Gln1062fs*1)
15 ND ND [21, 22]
T2 c.2569G>T, p.(Gly857*) 15 ND ND
F 26 yr c.524delC, 
p.(Thy175Metfs*10)
4 T1 c.2656C>T, p.(Gln886*) 15 – ND [21, 22]
T2 c.4606G>T, 
p.(Glu1536*)
15 – ND
T3 c.4666_4667insA, 
p.(Thr1556fs*3)
15 – ND
T4 + ND
T5 + ND
F 24 yr c.2093T>G, 
p.(Leu698*)
15 c.4362_4567ins159, 
p.(Lys1454fs*3)
15 ND ND [11]
F 21 yra c.832C>T, p.(Gln278*) 7 c.1363_1378delinsTTT 
CTC , p.(Lys455Phefs*9)
10 ND ND [23]
F 48 yra c.832C>T, p.(Gln278*) 7 – ND ND [23]
M 42 yr Duplication 2/3 – ND – [12]
F 27 yr c.1917insA, 
p.(Arg640Thrfs*11)
14 ND ND ND [24]
F 40 yr c.3149delC, 
p.(Ala1050Glufs*6)
15 ND ND ND [24]
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Table 1  (continued)
Sex age Germline pathogenic 
APC variant
Exon T Somatic pathogenic APC 
variant
Exon LOH Somatic patho-
genic CTNNB1 
variant
Exon References
F 32 yr ‘abnormal splicing in 
exon 9’; molecular 
defect not identified
9 ND ND ND [18, 25]
F 29 yr c.3927_3931del, 
p.(Glu1309Aspfs*4)
15 ND ND ND [26]
F 30 yr c.419_422del, 
p.(Glu140Glyfs*28)
3 – ND ND [27]
F 19 yr c.1775T>G 
p.(Leu592*)
14 – ND ND [27]
F 22 yr c.2336del p.(Leu779*) 15 – ND ND [27]
F 18 yr c.2928_2929del, 
p.(Gly977Serfs*7)
15 – ND ND [27]
F 27 yr c.2979del, 
p.(Lys993Asnfs*12)
15 – ND ND [27]
F 39 yr c.3183_3187del, 
p.(Gln1062*)
15 – ND ND [27]
F 26 yr c.3927_3931del, 
p.(Glu1309Aspfs*4)
15 – ND ND [27]
F 22 yrb c.3183_3187del, 
p.(Gln1062*)
15 – ND ND [27]
F 20 yrb c.3183_3187del, 
p.(Gln1062*)
15 – ND ND [27]
F 36 yrb c.3183_3187del, 
p.(Gln1062*)
15 – ND ND [27]
F 24 yr c.3183_3187del, 
p.(Gln1062*)
15 – ND ND [27]
F 20 yr c.3927_3931del, 
p.(Glu1309Aspfs*4)
15 – ND ND [27]
F 27 yr c.3927_3931del, 
p.(Glu1309Aspfs*4)
15 – ND ND [27]
F 20 yr c.3183_3187del, 
p.(Gln1062*)
15 ND ND ND [28]
F 38 yr c.2093T>A, 
p.(Leu698*)
15 – ND ND [11]
F 49 yr c.937_938delGA, 
p.(Glu313Asnfs*)
9 – ND ND [11]
F 16 yrc c.254A>T, p.(Lys848*) 15 ND ND ND [29, 30]
F 12 yrc c.254A>T, p.(Lys848*) 15 ND ND ND [29, 30]
F 18 yr c.3183_3187del, 
p.(Gln1062*)
15 ND ND ND [31]
F 30 yr c.3317delG, 
p.(Gly1106Glufs*20)
15 ND ND ND [32]
F c.2211C>G, 
p.(Tyr737*)
15 ND ND [33]
F 40 yr Unknown variant in 
codon 1219
15 – ND ND [27]
F 19 yr Unknown variant in 
codon 1219
15 – ND ND [27]
F 35 yr – c.1559_1563delGCTCT, 
p.(Cys520fs*15)
12 ND – [34]
F 19 yr – c.3927_3931delAAAGA, 
p.(Glu1309fs*4)
15 ND ND [35]
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PTC rearrangements have also been reported in sporadic 
CMV-PTC [38], and in FAP associated cases [11, 12]. High 
rates of RET/PTC gene activation have been reported by 
Cetta et al. [39] in cases with heterozygous APC genes, 
although somatic mutations were not determined [22], with 
hypotheses of a tissue-specific dominant effect [40]. Somatic 
PIK3CA c.1634 A>C (p.E545A) mutations were reported 
in three sporadic CMV-PTC cases of female patients aged 
14, 16, 17 years [41], and suggested as a potential candi-
date gene involved in sporadic CMV-PTC tumorigenesis in 
absence of a CTNNB1 mutation, however, APC gene muta-
tion data are lacking. A 16-year old female FAP patient was 
reported with a somatic KRAS mutation (c. 181C>A (p. 
Q61K)); however, data on APC (or CTNNB1) genes were 
not reported [42].
Discussion
In the present report we describe a young adult patient with 
cribriform-morular variant of PTC with biallelic somatic 
inactivating APC variants. To the best of our knowledge, 
it represents the first case of two pathogenic somatic APC 
variants explaining the disease occurrence.
The class 5 APC variant c.3183_3187delACAAA, p. 
(Gln1062*), has previously been described as a germline 
pathogenic variant in a FAP patient with PTC [43]. The 
other APC variant c.3124delA, p. (Ser1042Valfs*14) was 
not reported before, but was considered a class 4 (likely 
pathogenic) variant. The pathogenicity of variants is anno-
tated in classes 1 to 5, with a class 4 variant being likely 
pathogenic and a class 5 variant being (well-known) patho-
genic [44], based on literature (Pubmed) search and com-
mon or locus specific databases (Mycancergenome, Alamut 
Visual, NCBI dbSNP, NCBI ClinVar, COSMIC, Jackson 
laboratory database, LOVD, MD Anderson database).
Also, the finding of a solitary nodule in our patient, is in 
line with its usual appearance in sporadic cases [1].
The detection of the biallelic inactivating mutations is in 
line with the Knudson “two-hit hypothesis” [45], supporting 
the underlying nature for the tumor.
Germline variants in APC are frequently found in FAP 
patients, but absent in the CTNNB1 gene [46, 47]. The 
occurrence of a germline CTNNB1 variant has only been 
reported as an inactivating mutation, constituting another 
distinct phenotype without tumor manifestations, in two 
siblings, of whom the parents most likely harbored ger-
mline mosaicism [48]. Cetta et al. reported that biallelic 
inactivation of APC is usually lacking in thyroid carci-
noma cases occurring in FAP [49]. The latter might be 
suggestive of a conveyance of a general susceptibility to 
thyroid tumorigenesis [50]. On the other hand, this could 
also be partly due to a limited or a lack of mutational 
analysis of the APC and/or CTNNB1 gene (indicated as 
ND, not determined, in Table 1).
The CTNNB1 variants in the cases listed in the over-
view (Table 1) were all located on exon 3, which is typi-
cally associated with β-catenin translocation from mem-
brane to nucleus and Wnt pathway activation [51].
The majority of the reported somatic and germline APC 
variants in CMV-PTC (Table 1, [27]), were not within 
the mutation cluster region (MCR) in APC (codons 
1286–1513) for somatic mutations in colorectal tumors 
[52]. Of the reported 17 somatic APC variants, 3 variants 
occurred in, 12 before and 2 after the MCR, respectively 
(Table 1). Of the reported 36 germline APC variants, 4 
occurred in and 31 before the MCR (one of the germline 
variants was a whole gene deletion) (Table 1).
Table 1  (continued)
Sex age Germline pathogenic 
APC variant
Exon T Somatic pathogenic APC 
variant
Exon LOH Somatic patho-
genic CTNNB1 
variant
Exon References
F 27 yr – c.3927_3931delAAAGA, 
p.(Glu1309fs*4)
15 ND ND [36]
References are listed in the appendix. Data in the table are ordered according to somatic CTNNB1 mutations, then the germline APC vari-
ants (either coinciding with somatic mutations or without other mutations) and somatic APC mutations reported in literature. Within the list, a 
reverse chronological order has been pursued with annotation of the variants according to HGVS guidelines. The majority of somatic variants 
were found in the COSMIC database. Printed underlined: Germline variants found in ClinVar. The remaining variants were found in LOVD. 
Variants reported were curated and annotated using the APC reference sequence NM_000038.5
– No variants detected, bp base pair, del deletion, F female, M male, ND not determined, T1, T2, etc. number of tumor foci, yr years old
a Related cases (mother, daughter) belonging to the same kindred
b,c Related cases (sisters) belonging to the same kindred, respectively
d Somatic variants not found in COSMIC database
e 1 base pair downstream of exon 12
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However, all germline APC variants (Table 1) were 
within the region extending from codons 140 to 1309, 
that has been associated to PTC in terms of genotype-phe-
notype correlations of extra-intestinal manifestations of 
FAP [39, 53, 54]. Of the 17 reported somatic APC variants 
(Table 1), 3 variants were out of and 14 variants were in 
this region (codons 140–1309), as well as the two somatic 
APC variants identified in the index patient.
In conclusion, in the current study, we report biallelic 
somatic (rather than germline) pathogenic APC variants 
in a young female CMV-PTC patient. Our report corrobo-
rates current ideas regarding the molecular background in 
CMV-PTC tumors. The true somatic nature of the variants 
found, was rendered most likely, using deep APC sequenc-
ing of leukocyte and normal DNA to exclude mosaicism. 
Accordingly, endoscopy was not performed. With a sub-
stantial share of FAP patients having a de novo APC muta-
tion [4, 5], the presently reported approach conveys added 
value and clinical relevance especially in patients with 
an absent family history of FAP. As much so in patients 
without any evidence of detected FAP as of yet, with about 
60% of total CMV-PTC being FAP associated, of whom a 
substantial proportion is preceded by that of thyroid can-
cer [1].
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